PALTECH: THE FIRST TREATMENT ENABLING A SUSTAINED REMISSION OF TYPE 2 DIABETES AND OBESITY CARE

A NEW PARADIGM IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY

OUR VISION : FOR A SUSTAINED LONG TERM T2D REMISSION

PALTECH DEVELOPS A NEW INNOVATIVE TREATMENT FOR TYPE 2 DIABETES AND OBESITY

A long lasting implant for people suffering from Type 2 Diabetes and obesity
Upregulation of deficient portal GLP-1 receptors
First class pre-clinical results
Filing for FIH in 2025

PALTECH IN A NUTSHELL

Funded by an INRAE professor, Business minded Diabetologist and Entrepreneurs, with previous successful experiences

CREATED IN 2021

Development of the Proof Of Concept
Launch of the preclinical phase
Results already obtained in animals
Funding : Private (fund raising) and Public (2 grants from French State / BPI)

STRONG IP

5 Patents filed

SOLID SCIENTIFIC DATA PROVEN RESULTS

A solid corpus of peer reviewed data, showing a unique MOA to induce a sustained T2D remission for multiple years

A BREAKTHROUGH FROM CURRENT PRACTICE

A Current T2D medical treatments show limited sustained efficacy due to poor adherence & persistence rates, significant adverse effects.

Metabolic surgeries are very invasive, their follow-up is resource demanding for both patients and HCPs, they are limited in numbers and provide 5 years T2D remissions in only 30-50% cases